{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:50:38Z","timestamp":1774079438584,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objective: This study aimed to elucidate the association between hematologic toxicity (HT) and pelvic bone marrow (PBM) dosimetric parameters in patients with cervical cancer (CC) undergoing radiotherapy (RT) combined with artificial intelligence (AI)-assisted organ at risk (OAR) delineation (Software Copyright Registration Number 2023SR0150365). Accurate delineation of bone marrow (BM) regions and analysis of radiation doses may provide a theoretical foundation for the application of AI in predicting HT. Methods: This retrospective study included 141 patients with CC who received chemotherapy (sequential or concurrent) and\/or pelvic volumetric modulated arc therapy (VMAT) at the Department of Gynecology, Cancer Hospital of the Chinese Academy of Medical Sciences, between March 2019 and December 2019. PBM and its subregions (ilium, lower pelvis, lumbosacral spine, and femoral heads) were delineated using AI-based automatic segmentation of CT images. The volumes receiving 10\u201340 Gy (V10, V20, V30, V40) were calculated, and baseline clinical characteristics were assessed. HT endpoints included grade \u2265 2 (HT2+) and grade \u2265 3 (HT3+) leukopenia, neutropenia, anemia, or thrombocytopenia. Associations between dosimetric parameters and HT were evaluated using logistic regression models. Results: Of the 141 patients, 107 (75.8%) developed HT2+ and 33 (23.4%) developed HT3+. Univariate analysis showed that chemotherapy and age were correlated with HT2+. Multivariate analysis identified femoral head V30, femoral head V40, and chemotherapy as independent predictors of HT3+. Conclusions: This study highlights the potential of AI-based OAR delineation for assessing PBM dosimetric parameters in patients with CC. Optimizing RT to minimize BM dose and volume may mitigate HT and enhance treatment tolerance. In our cohort, receipt of combined neoadjuvant and concurrent chemotherapy (NACT+CCRT) was a stronger predictor of HT than most BM dosimetric parameters, suggesting that the systemic effect of chemotherapy may dominate the hematologic toxicity profile in this setting. Consequently, patients receiving this combined modality treatment are at particularly high risk for HT and warrant close hematologic monitoring.<\/jats:p>","DOI":"10.3390\/cancers18060992","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:49:24Z","timestamp":1773924564000},"page":"992","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation Between Dosimetric Parameters and Hematologic Toxicity in Cervical Cancer Patients Undergoing Intensity-Modulated Pelvic Radiotherapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5319-4363","authenticated-orcid":false,"given":"Shuang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-9957","authenticated-orcid":false,"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-9375","authenticated-orcid":false,"given":"Shuangzheng","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jusheng","family":"An","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manni","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"218286","DOI":"10.1016\/j.canlet.2026.218286","article-title":"Cervical Cancer Incidence and Mortality Trends in China: The Role of Screening","volume":"642","author":"Yuan","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0167-8140(03)00197-X","article-title":"A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer","volume":"68","author":"Kirwan","year":"2003","journal-title":"Radiother. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/IGC.0000000000001216","article-title":"The European Society of Gynaecological Oncology\/European Society for Radiotherapy and Oncology\/European Society of Pathology guidelines for the management of patients with cervical cancer","volume":"28","author":"Cibula","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-018-1126-7","article-title":"Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis","volume":"13","author":"Lin","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jrr\/rry054","article-title":"Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric arc radiotherapy in cervical cancer treatment: Applying the central shielding principle to modern technology","volume":"59","author":"Tamaki","year":"2018","journal-title":"J. Radiat. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Konnerth, D., Gaasch, A., Zinn, A., Rogowski, P., Rottler, M., Walter, F., Knoth, J., Sturdza, A., Oelmann, J., and Grawe, F. (2024). Hematologic Toxicity and Bone Marrow-Sparing Strategies in Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review. Cancers, 16.","DOI":"10.3390\/cancers16101842"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2009.11.040","article-title":"Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging","volume":"79","author":"Hayman","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","article-title":"Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Campos","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijrobp.2014.06.061","article-title":"Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer","volume":"90","author":"Han","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Patel","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2013.01.017","article-title":"Hematologic toxicity in RTOG 0418: A phase 2 study of postoperative IMRT for gynecologic cancer","volume":"86","author":"Klopp","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","first-page":"207","article-title":"Identification of pelvic dose-volumetric parameters that predict acute bone marrow suppression in concurrent chemoradiotherapy for cervical cancer","volume":"36","author":"Huang","year":"2016","journal-title":"Chin. J. Radiol. Med. Prot."},{"key":"ref_13","first-page":"48","article-title":"Correlation factors of bone marrow suppression in concurrent chemoradiotherapy for cervical cancer","volume":"19","author":"Niu","year":"2013","journal-title":"J. Tianjin Med. Univ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.2147\/CMAR.S195989","article-title":"Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation","volume":"11","author":"Kumar","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/0284186X.2015.1043396","article-title":"Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma","volume":"55","author":"Julie","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.V89.7.2303","article-title":"Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model","volume":"89","author":"Manus","year":"1997","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-023-02248-x","article-title":"The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy","volume":"18","author":"Chen","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cheng, Y.K., Ma, Y., Zheng, J., Deng, H., Wang, X., Li, Y., Pang, X., Chen, H., He, F., and Wang, L. (2019). Impact of chemotherapy regimens on normal tissue complication probability models of acute hematologic toxicity in rectal cancer patients receiving intensity-modulated radiation therapy with concurrent chemotherapy from a prospective phase III clinical trial. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00244"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","article-title":"Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy","volume":"66","author":"Mell","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pro6.70019","article-title":"Dosimetric and hematological toxicity analyses of bone marrow-sparing intensity-modulated radiation therapy for patients with cervical cancer treated with extended-field radiation therapy","volume":"9","author":"Wang","year":"2025","journal-title":"Precis. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13014-024-02432-7","article-title":"Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: A prospective phase II randomized controlled study","volume":"19","author":"Li","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Huang, W., Dang, J., Li, Y., Cui, H.X., Lu, W.L., and Jiang, Q.F. (2021). Effect of pelvic bone marrow sparing intensity-modulated radiation therapy on acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.646211"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15330338241255283","DOI":"10.1177\/15330338241255283","article-title":"Dose-Volume Parameters of Spared Magnetic Resonance Imaging-Defined Active Bone Marrow Predict Hematologic Toxicity in Pelvic Malignancies Patients Undergoing Radiotherapy: A Cohort Study","volume":"23","author":"Gao","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4103\/ijc.IJC_585_20","article-title":"Dosimetric correlation of bone marrow irradiation with acute hematological toxicity in concurrent chemoradiation of cervical carcinoma patients","volume":"60","author":"Pruthi","year":"2023","journal-title":"Indian J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13014-023-02205-8","article-title":"The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer","volume":"18","author":"Zhang","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92904","DOI":"10.18632\/oncotarget.21646","article-title":"Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13014-020-01606-3","article-title":"Pelvic bone marrow sparing intensity-modulated radiotherapy reduces the incidence of hematologic toxicity in patients with cervical cancer receiving concurrent chemoradiotherapy: A single-center prospective randomized controlled trial","volume":"15","author":"Huang","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1002\/cam4.2601","article-title":"The volume of 99mTc sulfur colloid SPECT-defined active bone marrow can predict grade 3 or higher acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.4103\/jcrt.jcrt_924_21","article-title":"Relationship of irradiated bone marrow volume and neutropenia in patients undergoing concurrent chemoradiation therapy for cervical cancer","volume":"18","author":"Antony","year":"2022","journal-title":"J. Cancer Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0587.2012.07348.x","article-title":"Collinearity: A review of methods to deal with it and a simulation study evaluating their performance","volume":"36","author":"Dormann","year":"2013","journal-title":"Ecography"},{"key":"ref_31","first-page":"211","article-title":"An overview of artificial intelligence in medical physics and radiation oncology","volume":"3","author":"Liu","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1002\/mp.16468","article-title":"Delineation of clinical target volume and organs at risk in cervical cancer radiotherapy by deep learning networks","volume":"50","author":"Tian","year":"2023","journal-title":"Med. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e13470","DOI":"10.1002\/acm2.13470","article-title":"Deep learning-based auto-segmentation of clinical target volumes for radiotherapy treatment of cervical cancer","volume":"23","author":"Ma","year":"2022","journal-title":"J. Appl. Clin. Med. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/992\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:24:19Z","timestamp":1774070659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060992"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060992","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}